CLAIMS

1. A multispecific antibody or fragment thereof that specifically binds:
   a. a first target epitope, wherein the first target epitope is an epitope of the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR); and
   b. a second target epitope, wherein the second epitope is selected from the group consisting of an epitope of CD19, Her2 (CD340), EGFR, FAPα, mesothelin, PD-1, 4-1BB, OX40 and TIGIT.

2. The multispecific antibody or fragment thereof of claim 1, wherein the second target epitope is an epitope of CD19.

3, The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of Her2 (CD340).

4. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of EGFR.

5. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of FAPα.

6. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of mesothelin.

7. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of PD-1.

8. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of 4-1BB.

9. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of OX40.

10. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of TIGIT.

11. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an epitope comprising one or more amino acid residues within amino acid regions:
   (i) 3-20 of SEQ ID NO: 1; and/or

(ii) 37-77 of SEQ ID NO: 1.

12. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an activating epitope of a γδ T cell.

13. The multispecific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein binding of the activating epitope: (i) downregulates the γδ TCR; (ii) activates degranulation of the γδ T cell; and/or (iii) promotes γδ T cell mediated killing.

14. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an epitope that upregulates expression of CD107a, CD25, CD69 and/or Ki67.

15. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or fragment thereof binds the first epitope with a binding affinity (KD) as measured by surface plasmon resonance of less than 1.5×10^{-7} M, less than 1.3×10^{-7} M, less than 1.0×10^{-7} M, or less than 5.0×10^{-8} M.

16. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the antibody is a bispecific antibody.

17. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or fragment thereof is a human antibody or antigen-binding fragment thereof.

18. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or antigen-binding fragment thereof is an IgG multispecific antibody, optionally wherein the multispecific antibody or antigen-binding fragment thereof is an IgG1 multispecific antibody.

19. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody is Fc-enabled.

20. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody is characterised in that it:
    a. causes downregulation of TCRs on Vδ1 T-cells;
    b. does not exhibit CDC or ADCC; and
    c. does not deplete Vδ1 T-cells.

21. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody causes a depletion of less than about 30%, or less than about 20%, or less than about 10% of the viable Vδ1 T+ cell population via ADCC and/or CDC.

22. A pharmaceutical composition comprising the multispecific antibody or fragment thereof as defined in any one of claims 1 to 21 and a pharmaceutically acceptable diluent or carrier.

23. A multispecific antibody or fragment thereof of any one of claims 1 to 21, or the pharmaceutical composition of claim 22, for use in treating a disease or disorder in a subject.

24. The multispecific antibody or fragment thereof for use according to claim 23, wherein the disease or disorder is cancer, an infectious disease or an inflammatory disease.